Navigation Links
Asymmetrex Will Join RegMedNet Panel to Discuss New Developments in Regulatory Policies for Stem Cell Medical Research
Date:6/22/2017

For the months of May and June, United Kingdom-based social media network RegMedNet has produced a Spotlight series on “Cell Therapy Regulation” for its regenerative medicine followship. The series has featured scholarly reviews and perspectives by leading experts on the unique regulatory challenges of stem cell medical research.

Stem cell clinical trials present unique regulatory challenges that are not an issue in conventional pharmaceutical and biopharmaceutical clinical research. On the one hand, introducing patients’ own cells, and even cells from matched donors, so far has been observed to be a relatively safe medical procedure. However, the small numbers of patients enrolled in clinical trials thus far have precluded evaluations of the reproducibility of efficacious effects associated with some transplanted cells.

The Spotlight takes a global look at current and changing regulatory policy for stem cell medical research. Experts review and evaluate recent policy developments for government agencies in the U.S., Europe, Japan, Canada and other countries.

On June 27, the Spotlight series will feature an online panel discussion of the topic. Panelists include leaders in companies and agencies that support development of cell therapeutics. James L. Sherley, M.D., Ph.D., Director of Asymmetrex, is one of the invited panelists. Sherley adds a perspective that has been missing from recent panels of this type on many different aspects of cell therapy, in particular cell therapy regulatory policy.

An important role for medical research regulatory policy is insuring the quality of evaluated prospective medicines. In the case of regenerative stem cell medicine, meeting this charge was not fully possible previously. No suitable methods existed for quality control evaluation of the essential stem cells in treatment samples. Asymmetrex now markets a technology for this purpose. On the panel, Sherley will address how the availability of a means for determining treatment stem cell quality and dose may impact future developments in stem cell medical research regulatory policies.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the quality and dose of tissue stem cell preparations (the “AlphaSTEM Test”) for use in stem cell transplantation therapies and in pre-clinical assays for drug safety.

Read the full story at http://www.prweb.com/releases/2017/06/prweb14449131.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Asymmetrex Director Comments on Positive Attributes of Private Stem Cell Clinics
2. Asymmetrex Named One of the "50 Most Valuable Brands of the Year 2017" by The Silicon Review
3. Asymmetrex Presents Adult Tissue Stem Cell Counting at the Alliance for Regenerative Medicine’s First Partnering Conference, May 22-23
4. At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific Quality Control Test for Therapeutic Tissue Stem Cells
5. Asymmetrex’s Head Will Lead Discussion on Supplying Private Stem Cell Clinics at the 6th Annual Clinical Trial Supply New England 2017 Conference in Boston
6. Asymmetrex's AlphaSTEM Test Adult Tissue Stem Cell Counting Technology Established to Be a Leading Interest for Regenerative Medicine in 2016
7. Asymmetrex Director Shares Vision for Company and Private Stem Cell Treatment Clinics in Two Arena International Event Group Forums
8. Asymmetrex Presents Technologies to Accelerate Gene-Editing Therapeutics Progress
9. Asymmetrex Continues Efforts to Raise Awareness of the Importance of Tissue Stem Cell Counting for Advancing Gene-Editing Therapeutics
10. In a Scheduled March 22 RegMedNet Webinar, Asymmetrex Discusses the Strategy for Its AlphaSTEM Technology for Counting Adult Tissue Stem Cells
11. In Upcoming Webinar and Conferences, Asymmetrex Will Intensify Education on Counting Adult Tissue Stem Cells For Regenerative Medicine and Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/11/2019)... ... , ... In this live webinar, the featured speakers will focus on the ... Participants will learn how to use the information they have from the protocol and ... complex randomization scheme is properly designed and set up to ensure flawless execution. As ...
(Date:3/5/2019)... ... March 05, 2019 , ... San Fransisko, or Sisko for short, ... at four years old to pursue a career in dressage. According to Deborah, ... talented horse that she’d ever worked with. Unfortunately, Sisko suffered an injury while ...
(Date:2/27/2019)... ... February 26, 2019 , ... Superior Controls, Inc., a ... with 140 employees on both the east and west coasts, today announced that ... of New Hampshire. Sandmaier, a senior project engineer, joins Taggart McCormick, P.E., Anthony ...
(Date:2/22/2019)... ... February 20, 2019 , ... Ocean Tomo Transactions, LLC ... , The patents in lot 92 relate to innovation for ... distinguish between human users and computers through exploiting the fundamental differences between computer-based ...
Breaking Biology Technology:
(Date:3/9/2019)... ... 2019 , ... Hello Bio announces the launch of novel ... studying GPCR and DREADD signalling. Hello Bio has been granted a license from ... and Stroke, both institutes of the National Institutes of Health, as well as ...
(Date:3/1/2019)... ... March 01, 2019 , ... Geneious would like to announce it is ... to Vector NTI. , Geneious Prime already has a dedicated importer for Vector ... so that files will be organised in Geneious in the same way. The ...
(Date:2/27/2019)... ... February 27, 2019 , ... Fluxion Biosciences, a leading developer of ... a National Cancer Institute grant for further development of its ERASE-Seq liquid biopsy technology. ... from the lab of Dr. Omar Mian at the Cleveland Clinic. , Liquid biopsies ...
Breaking Biology News(10 mins):